Back to news

Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date

Business Wire•20/11/2026•08:30 ET
0

Key Highlights

  • ➤FDA will not meet November 22, 2026 PDUFA date for molgramostim BLA
  • ➤Molgramostim BLA review remains ongoing with no revised FDA action date
  • ➤Savara’s investigational treatment targets autoimmune pulmonary alveolar proteinosis

Expert Statements

Matt Pauls, Chair and Chief Executive Officer of Savara

“We appreciate the FDA’s continued efforts on our application and look forward to working closely with the agency to complete its review”

Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date

Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has communicated that it will not meet the Prescription Drug User Fee Act (PDUFA) target action date of November 22, 2026 for the Company’s molgramostim inhalation solution (molgramostim) Biologics License Application (BLA) for the treatment of autoimmune PAP. The review of the BLA is ongoing and no revised action date has been provided by the agency.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in